evipedia.ai
← Back

NMN for Health & Longevity

Evidence Review created on 10/10/2026 using AI4L / Opus 5.5

Also known as: Nicotinamide Mononucleotide, β-Nicotinamide Mononucleotide, Beta-Nicotinamide Mononucleotide, β-NMN, MIB-626, Uthever

Motivation

Nicotinamide mononucleotide (NMN) is a compound derived from vitamin B3 that the body turns into a helper molecule every cell needs to convert food into energy and to repair damaged DNA. Levels of that helper molecule fall with age in several tissues, and NMN is sold as a supplement intended to restore them. It has become one of the most widely discussed compounds among people pursuing a longer healthy life.

Interest grew after laboratory experiments in mice examined whether topping up this helper molecule could influence features of aging. Since then, a series of small human studies has tested NMN in middle-aged and older adults, looking at metabolic health, physical performance and sleep. Its legal standing as a supplement in the United States has also changed more than once in recent years, which added to public attention.

This review examines the human and animal evidence on the potential benefits of NMN, its risks, the doses that have been studied, and the practical questions that matter to health-focused adults who are weighing it as part of a longevity strategy.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary on NMN and on NAD+ (nicotinamide adenine dinucleotide, a coenzyme that cells need for energy production and DNA repair), the molecule NMN is meant to raise.

Content from Chris Kresser was not included: his directly relevant item, a 2020 podcast interview with David Sinclair that discusses NMN, largely repeats Sinclair’s views already covered by the Huberman Lab episode, and the list is capped at five items.

Grokipedia

Nicotinamide mononucleotide

A broad AI-written overview of NMN chemistry, dietary sources, preclinical findings, human trial doses and regulatory history; useful orientation, though its summary of human efficacy is more favorable than pooled trial data.

Examine

Nicotinamide Mononucleotide

Examine’s independent summary concludes that aging-related benefits seen in animals remain unproven in humans, and its study notes flag null meta-analyses on glucose and lipids.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

Independent quality testing of NMN and other NAD-booster products, with safety notes on upper intake limits and dated clinical and product updates; much of the detail sits behind a paywall.

Systematic Reviews

This section lists systematic reviews and meta-analyses of randomized controlled trials (RCTs) of oral NMN in adults, covering safety and the main efficacy outcomes.

Mechanism of Action

NMN is NAD+’s immediate precursor. In cells, NMNAT (nicotinamide mononucleotide adenylyltransferase, the enzyme that finishes NAD+ assembly) converts NMN to NAD+, bypassing NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting recycling enzyme) (Yoshino et al., 2011). NAD+ carries electrons in energy metabolism and is consumed by sirtuins (proteins regulating metabolism and stress responses), PARPs (poly-ADP-ribose polymerases, DNA-repair enzymes) and CD38 (an immune-cell NAD+-degrading enzyme that rises with age) (Chini et al., 2020). Rationale: replenishing age-depleted NAD+ restores these processes.

Competing explanations exist:

  • Intact uptake: a gut transporter, Slc12a8, was reported in mice (Grozio et al., 2019; an author correction followed), but was disputed (Schmidt & Brenner, 2019).
  • Breakdown first: in mice, oral NMN is largely converted to nicotinamide in the liver (Liu et al., 2018); a human trial plus gut-microbe experiments suggest NMN raises blood NAD+ partly after bacterial conversion to nicotinic acid (Christen et al., 2026; Nestlé-run).
  • Potential downside: a high NMN-to-NAD+ ratio activates SARM1 (an NAD+-destroying enzyme in nerve fibers), triggering axon degeneration experimentally (Figley et al., 2021).

Pharmacology: NMN is a water-soluble nucleotide with no selective receptor. In mice, plasma NMN clears within about 15 minutes while tissue NAD+ rises (Mills et al., 2016; co-authored by NMN producer Oriental Yeast); human plasma half-life is unknown. Surplus nicotinamide is methylated by NNMT (nicotinamide N-methyltransferase) and excreted as 2PY and 4PY (terminal niacin breakdown products); little appears unchanged in urine (Pencina et al., 2023; MIB-626 developer co-authors). CYP (cytochrome P450) drug-metabolizing enzymes play no known role.

Historical Context & Evolution

NMN was identified in the mid-20th century as an NAD+ synthesis intermediate and studied for decades as basic biochemistry, not therapy. Its health use began with mouse research: in 2011, Shin-ichiro Imai’s laboratory reported that NMN restored NAD+ and improved glucose tolerance in diet- and age-induced diabetic mice (Yoshino et al., 2011), and a 12-month study found NMN limited age-associated weight gain, insulin resistance and eye-function decline in normal mice without obvious toxicity (Mills et al., 2016). Interest grew through David Sinclair’s books and podcasts; Sinclair co-founded Metro International Biotech, developer of the pharmaceutical NMN formulation MIB-626.

Human research began with single-dose safety studies in Japan (Irie et al., 2020), then small randomized trials, notably a 2021 study in prediabetic women (Yoshino et al., 2021). Charles Brenner, who has served as chief scientific adviser to ChromaDex, a seller of the competing precursor NR, argued that the trial’s groups were unbalanced in liver fat (Brenner, 2021); the authors defended their findings (Klein & Yoshino, 2021).

Opinion has moved in both directions. Pooled human trials showed no effect on glucose or lipids (Chen et al., 2024), while later syntheses found endurance and blood-pressure signals (Gao et al., 2026; Zhang et al., 2026) and a preprint reported a female-only mouse lifespan gain (Kane et al., 2024; Sinclair co-authored). Regulation shifted: the FDA (Food and Drug Administration) excluded NMN from supplements in 2022 and reversed this in September 2025, as reported by NutraIngredients alongside FDA’s new dietary ingredient list (FDA’s response letter, FDA-2023-P-0872-2754, unretrievable).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the clinical endpoints and validated surrogates measured so far (blood pressure, walking and endurance tests, quality-of-life scales) come from small trials of 4–24 weeks in which significant effects were shown by single research groups rather than replicated independently.

Medium 🟩 🟩

Modest Reduction in Diastolic Blood Pressure ⚠️ Conflicted

Diastolic pressure (the lower blood-pressure number) fell slightly in pooled trials. A 2026 meta-analysis of 10 RCTs found a small diastolic drop and a systolic drop only in adults aged 60 or older (Zhang et al., 2026); a second meta-analysis agreed (Yang et al., 2026). Single trials mostly found no change, e.g., in prediabetic women (Yoshino et al., 2021); only Pencina’s MIB-626 trial, run with developer Metro International Biotech, reported −7 mmHg (Pencina et al., 2023). Net reading: a small pooled diastolic effect.

Magnitude: Diastolic blood pressure −2.15 mmHg versus placebo (95% CI −3.68 to −0.61; CI = confidence interval, the range likely to contain the true effect); systolic change not significant overall, but −3.94 mmHg (95% CI −7.06 to −0.82) in participants aged 60 or older (Zhang et al., 2026).

Aerobic Endurance and Walking Capacity ⚠️ Conflicted

In amateur runners training for 6 weeks, 600–1,200 mg/day raised oxygen uptake at ventilatory thresholds (intensities where breathing rises sharply) (Liao et al., 2021). In 80 healthy middle-aged adults, 300–900 mg/day lengthened six-minute walk distance in a trial run by NMN maker Abinopharm (Yi et al., 2023). A 28-day MIB-626 trial in overweight older adults found no aerobic-capacity change (Pencina et al., 2023). A network meta-analysis found dose-dependent endurance gains (Gao et al., 2026). Net reading: a small gain is likely in active adults, unconfirmed in older ones.

Magnitude: Endurance SMD (standardized mean difference, an effect size in standard-deviation units) 0.66 (95% CI 0.09 to 1.23) at medium doses and 1.02 (95% CI 0.43 to 1.60) at high doses versus placebo (Gao et al., 2026).

Self-Rated Health and Quality of Life

Scores on the SF-36 (a validated 36-item health-status questionnaire) improved more with 300–900 mg/day than with placebo over 60 days in the Abinopharm-run trial (Yi et al., 2023). A 60-day trial by supplier Effepharm reported a larger SF-36 rise with 300 mg/day than placebo (6.5% versus 3.4%), without a between-group test in its abstract (Huang, 2022). A network meta-analysis found moderate quality-of-life gains (Gao et al., 2026). Both source trials were manufacturer-run, so only one clearly significant trial underpins this item.

Magnitude: Quality of life SMD 0.56 (95% CI 0.14 to 0.98) at high doses and 0.45 (95% CI 0.11 to 0.78) at low doses versus placebo (Gao et al., 2026).

Low 🟩

Muscle Insulin Sensitivity ⚠️ Conflicted

In 25 prediabetic women, 250 mg/day for 10 weeks raised muscle insulin sensitivity (Yoshino et al., 2021). A 28-day MIB-626 trial found no such change (Pencina et al., 2023); pooled trials showed no fasting-glucose or HOMA-IR (insulin-resistance index) effect (Chen et al., 2024). Net reading: the muscle effect is unconfirmed.

Magnitude: Insulin-stimulated glucose disposal rose 25 ± 7% (± gives the reported spread around the average) after NMN and did not change after placebo (not compared between groups) (Yoshino et al., 2021); pooled fasting glucose, insulin, HbA1c (3-month average blood sugar) and HOMA-IR showed no significant difference versus placebo (Chen et al., 2024).

Lipids and Body Weight ⚠️ Conflicted

One 28-day MIB-626 trial at 2,000 mg/day lowered LDL (low-density lipoprotein) cholesterol and body weight versus placebo (Pencina et al., 2023). A meta-analysis of 15 RCTs found no effect on lipids, weight or BMI (body mass index) (Yang et al., 2026). Net reading: the single positive trial is not reproduced.

Magnitude: LDL cholesterol −18.73 mg/dL (95% CI −31.85 to −5.60) and body weight −1.9 kg (95% CI −3.3 to −0.5) versus placebo (Pencina et al., 2023).

Arterial Stiffness ⚠️ Conflicted

In 36 healthy middle-aged adults, 250 mg/day for 12 weeks did not significantly lower pulse wave velocity (a measure of arterial stiffening) versus placebo, though subgroups with higher BMI or blood glucose improved (Katayoshi et al., 2023; supplement maker DHC-run). Net reading: unproven.

Magnitude: Brachial-ankle pulse wave velocity fell 25 cm/s (−2.1%) with NMN and rose 6 cm/s (+0.5%) with placebo over 12 weeks; the between-group difference was not significant, and no difference figure is reported (Katayoshi et al., 2023).

Muscle Strength and Gait Speed in Older Adults ⚠️ Conflicted

Small trials reported nominally faster gait (Igarashi et al., 2022; supplier Mitsubishi co-authors) or preserved walking speed (Morifuji et al., 2024; Meiji-run); another found no grip or gait gain (Akasaka et al., 2023; Teijin co-authors), and a meta-analysis agreed (Prokopidis et al., 2025). Net reading: no reliable benefit.

Magnitude: Gait speed −0.01 m/s (95% CI −0.08 to 0.06) and handgrip strength 0.61 kg (95% CI −0.89 to 2.10) versus placebo (Prokopidis et al., 2025).

Sleep Quality and Daytime Drowsiness ⚠️ Conflicted

In older adults, 250 mg/day improved Pittsburgh Sleep Quality Index scores versus placebo (Morifuji et al., 2024); afternoon NMN and placebo both reduced drowsiness (Kim et al., 2022; supplier co-authors). A network meta-analysis found no precursor improved sleep or fatigue (Gao et al., 2026). Net reading: weak, inconsistent signal.

Magnitude: Global Pittsburgh Sleep Quality Index score (lower is better) after 12 weeks 3.2 ± 1.4 with NMN versus 4.3 ± 1.5 with placebo (between-group P = 0.013, P being the probability of a difference this large arising by chance alone; no difference figure or CI reported) (Morifuji et al., 2024); pooled analysis found no significant sleep benefit (Gao et al., 2026).

Platelet Counts in Immune Thrombocytopenia ⭕️ Not Central to Health & Longevity

A single-arm trial gave 450 mg twice daily for 2 weeks to 25 adults with treatment-resistant immune thrombocytopenia (autoimmune platelet destruction) (Li et al., 2026). This bears on autoimmune blood disease, not healthy aging. Proposed mechanism: restoring macrophage NAD+ depleted by CD38.

Magnitude: 5 of 25 patients (20%) met the primary platelet-response endpoint, and 60% exceeded 1.5 times their baseline platelet count during treatment (no control group) (Li et al., 2026).

Speculative 🟨

Higher Blood NAD+ and Stable Biological-Age Scores

Blood NAD+ rises dose-dependently in controlled trials (Yi et al., 2023; Okabe et al., 2022, supplier co-authors), and a blood-age score stayed stable while placebo’s rose. Both are unvalidated biomarkers, not health outcomes.

Delayed Frailty and Longer Lifespan in Mice

In a preprint co-authored by Sinclair, lifelong NMN reduced frailty and extended median lifespan 8.5% in female mice only, without more tumors (Kane et al., 2024). Basis is animal data only.

Organ Protection in Disease Models

Rodent studies show NAD+ precursors protecting heart, kidney, brain and blood vessels in injury and disease models (review: Bhasin et al., 2023). No controlled human outcome data exist; basis is animal only.

Oocyte Quality ⭕️ Not Central to Health & Longevity

A systematic review of seven animal studies found NMN improved egg-cell mitochondrial function (Noh et al., 2026). This bears on fertility, not aging; basis is animal and gene-expression data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been linked to NMN benefit in humans. The variant rs10496731 is associated with higher 2PY and 4PY levels (Ferrell et al., 2024), which may influence metabolite handling.
  • Baseline NAD+ level and response: Whether low starting NAD+ predicts greater benefit is untested; NAD+ rises varied widely (coefficient of variation, spread relative to the mean, 29–113%), and larger rises tracked greater walking and SF-36 gains (Kuerec et al., 2024; Abinopharm co-author).
  • Sex: The muscle insulin-sensitivity signal came from women (Yoshino et al., 2021), several muscle trials enrolled only men (Igarashi et al., 2022), and the mouse lifespan gain was female-only (Kane et al., 2024).
  • Pre-existing conditions: Metabolic signals appeared mainly in overweight or prediabetic adults (Yoshino et al., 2021; Pencina et al., 2023); metabolic markers changed little in healthy middle-aged adults (Yi et al., 2023).
  • Age: The systolic blood-pressure effect was confined to adults aged 60 or older (Zhang et al., 2026), while muscle mass and strength did not respond in adults over 60 (Prokopidis et al., 2025).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: controlled human trials of up to 24 weeks at 250–2,000 mg/day report adverse-event rates similar to placebo, and the concerns raised rest on uncontrolled reports, observational metabolite data, animal studies or mechanism.

Medium 🟥 🟥

No risk reaches Medium: no controlled human trial has shown a harm on a clinical endpoint or validated surrogate; the signals below come from an uncontrolled case series, indirect metabolite associations, or animal and cell work.

Low 🟥

Mild Adverse Events ⚠️ Conflicted

In a single-arm trial, mild treatment-related adverse events occurred in 12% of patients (Li et al., 2026). A meta-analysis of RCTs found no increase in overall, serious or withdrawal-causing adverse events, nor in ALT or AST (liver enzymes) (Yang et al., 2026). Net reading: no excess over placebo.

Magnitude: Mild treatment-related adverse events in 3 of 25 patients (12%) at 900 mg/day (no control group) (Li et al., 2026); pooled RCTs showed a total adverse-event risk difference (the gap in event rates between groups) versus placebo of −0.8 percentage points (95% CI −6.1 to 4.5; not significant) (Yang et al., 2026).

Raised 4PY and Possible Cardiovascular Risk

NMN dose-dependently raises 2PY and 4PY in blood (Irie et al., 2020). In cohorts, higher 4PY predicted major cardiovascular events, and 4PY induced vascular inflammation in mice (Ferrell et al., 2024; a publisher correction was issued). Evidence is indirect: body levels from dietary niacin, not NMN.

Magnitude: Adjusted hazard ratio (HR, relative risk over time) for 3-year major adverse cardiovascular events with higher 4PY: 1.89 (95% CI 1.26 to 2.84) in a US cohort and 1.99 (95% CI 1.26 to 3.14) in a European cohort (Ferrell et al., 2024).

Speculative 🟨

Blunted Mitochondrial Adaptation to Exercise

In 11 young men, 1,200 mg/day for 7 days abolished the post-exercise rise in muscle mitochondrial content and dampened inflammatory signaling (Yang et al., 2026). Tissue markers only; no performance outcomes measured.

Kidney Inflammation in Older Animals ⚠️ Conflicted

High-dose NMN raised kidney-injury markers and kidney-cleared waste products in aged mice (Saleh et al., 2024, preprint). A supplier-run 1,250 mg/day trial found normal laboratory results (Fukamizu et al., 2022). Net reading: unconfirmed in humans.

Support of Tumor-Promoting Inflammation ⚠️ Conflicted

NAD+ metabolism drives tumor-promoting inflammatory secretions from senescent (aged, non-dividing) cells (Nacarelli et al., 2019). Lifelong NMN did not increase mouse tumors (Kane et al., 2024). Net reading: theoretical; cell and animal data only.

Axon Degeneration via SARM1

A rising NMN-to-NAD+ ratio activates SARM1 and destroys injured nerve fibers in experimental models (Figley et al., 2021; review: Loreto et al., 2023). Mechanistic only; not observed in human trials.

Methyl-Group Drain

Surplus nicotinamide is cleared by methylation; NMN raised methylated metabolites in muscle (Yoshino et al., 2021). Depletion of methyl donors and rising homocysteine are theoretical; mechanistic basis only.

Reproductive-Organ Effects at High Doses in Rats

A 90-day rat study showed reproductive-organ effects; EFSA (European Food Safety Authority) set the no-adverse-effect level at 400 mg/kg/day and judged 300 mg/day safe for adults (EFSA, 2026). Animal data only.

Risk-Modifying Factors

  • Genetic polymorphisms: Carriers of rs10496731 variants that raise 2PY and 4PY also show higher sVCAM-1 (soluble vascular cell adhesion molecule 1, a vascular-inflammation marker) (Ferrell et al., 2024); whether NMN adds risk in them is untested.
  • Baseline biomarkers: Reduced kidney function could favor accumulation of NMN breakdown products, as in aged mice (Saleh et al., 2024); low folate or B12 status could magnify methyl-group drain (theoretical).
  • Sex: Rat reproductive-organ effects at high doses and EFSA’s exclusion of pregnancy and lactation make reproductive status the main sex-related consideration (EFSA, 2026); no human sex difference in adverse events is reported.
  • Pre-existing conditions: Active or past cancer (theoretical tumor support), chronic kidney disease and peripheral neuropathy (nerve damage in the limbs; theoretical SARM1 activation) are the conditions where the speculative risks would matter most.
  • Age: Kidney inflammation appeared in aged but not young mice (Saleh et al., 2024), so the oldest users carry the largest theoretical exposure; the oldest trial cohort (mean age 81) had 14 participants (Akasaka et al., 2023; Teijin co-authors).

Key Interactions & Contraindications

No human drug-interaction study of NMN has been published; the interactions below are inferred from mechanism.

  • Other NAD+ precursors and niacin, including over-the-counter forms (nicotinamide, NR, nicotinic acid): Monitor (theoretical). Additive nicotinamide load; EFSA’s upper level for nicotinamide is 900 mg/day (EFSA, 2026). Nicotinic acid adds flushing; total intake from all sources sets the load.
  • Glucose-lowering drugs (metformin, insulin, sulfonylureas such as glimepiride): Monitor (theoretical). Improved muscle insulin sensitivity (Yoshino et al., 2021) could add to glucose lowering and risk low blood sugar, though pooled trials show no fasting-glucose change (Chen et al., 2024). Early glucose checks mitigate this.
  • Blood-pressure drugs (amlodipine, lisinopril, losartan): Monitor (theoretical). A small additive diastolic reduction (Zhang et al., 2026) could cause light-headedness in people already near low pressure; home readings in the first weeks mitigate this.
  • PARP inhibitor cancer drugs (olaparib, niraparib, talazoparib): Avoid (theoretical). These drugs exploit NAD+-dependent DNA-repair failure in tumors; extra NAD+ could blunt their effect. Oncology teams assess precursor use case by case.
  • Anti-CD38 antibodies (daratumumab, isatuximab): Caution (theoretical). CD38 blockade already raises NAD+, and NMN acts on the same pathway (Li et al., 2026); the combined effect on immune and tumor cells is unknown. Prescriber review mitigates this.
  • Supplements with additive NAD+ effects (apigenin, quercetin, resveratrol): Monitor (theoretical). CD38-inhibiting flavonoids and sirtuin activators may add to NMN’s effect on NAD+ pathways, with additive NAD+ elevation of unknown clinical significance.
  • Methyl donors (trimethylglycine, folate, choline): Possibly complementary (theoretical). Clearing surplus nicotinamide consumes methyl groups; co-supplementation is common and is being tested (NCT07144527). No interaction harm is expected.
  • Intense exercise training: Caution (theoretical). High-dose NMN taken around training blunted mitochondrial adaptation in muscle (Yang et al., 2026), with a potential cost to training gains. Dosing away from key sessions may mitigate this (untested).

Populations who should avoid NMN:

  • Pregnant or breastfeeding women: excluded from EFSA’s safety conclusion for lack of data (EFSA, 2026).
  • Children and adolescents: safety has been assessed only in adults (EFSA, 2026).
  • People with active cancer or receiving PARP-inhibitor therapy: avoid (theoretical).
  • People with advanced chronic kidney disease: caution (theoretical), based on aged-mouse data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Staying within tested doses: Trials used 250–2,000 mg/day for up to 24 weeks, and EFSA judged 300 mg/day safe (EFSA, 2026); staying in this range limits exposure to the untested high-dose kidney and reproductive signals.
  • Third-party-tested products: Products with lot-specific certificates of analysis prevent paying for capsules with little or no NMN, a problem documented in market testing (NutraIngredients).
  • Kidney and liver checks: Creatinine with eGFR (estimated glomerular filtration rate, kidney filtering capacity) and ALT at baseline and after 3 months detect the theoretical kidney signal and confirm liver tolerance; stopping if values leave the reference range limits harm.
  • Dosing away from hard training: Taking NMN away from key training sessions may reduce the blunting of mitochondrial adaptation seen with high doses (Yang et al., 2026); timing benefit is untested.
  • Adequate methyl-donor intake: Adequate folate, B12 and choline, with a homocysteine check, guards against the theoretical methyl-group drain from nicotinamide clearance.
  • Current cancer screening: Age-appropriate screening before and during long-term use addresses the theoretical risk of supporting tumor-promoting inflammation.
  • Glucose and blood-pressure checks on medication: Home glucose and blood-pressure checks in the first 2–4 weeks catch additive lowering with diabetes or blood-pressure drugs.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, cycling, titration) reflect common practice.

  • Dose range in trials: 250 mg/day in Japan (Okabe et al., 2022); 300–900 mg/day, with the best NAD+ and walking response at 600 mg (Yi et al., 2023); 1,000 mg once or twice daily as MIB-626 (Pencina et al., 2023).
  • Regulatory reference dose: EFSA judged 300 mg/day of β-NMN safe for adults, excluding pregnancy and lactation (EFSA, 2026).
  • Practitioner approach: David Sinclair, who popularized NMN, has described taking about 1 g each morning alongside resveratrol (Huberman Lab episode); his commercial ties to an NMN developer are noted above.
  • Alternative approaches: Skeptics such as Peter Attia call support for oral precursors almost entirely theoretical (Attia’s NMN trial critique); others favor NR, which raised blood NAD+ comparably (Christen et al., 2026), or exercise, which raises NAMPT (Sun et al., 2023).
  • Time of day: Morning dosing is common, aligned with daytime NAD+ rhythms; afternoon dosing produced the largest drowsiness and leg-function gains in older adults (Kim et al., 2022).
  • Half-life: In mice, plasma NMN clears within about 15 minutes (Mills et al., 2016); in humans, blood NAD+ stays raised with daily dosing over weeks, though a plasma half-life is not established.
  • Single versus split doses: Most trials used one daily dose; twice-daily 1,000 mg MIB-626 raised blood NMN exposure more than once-daily (3.7 versus 1.7 times baseline) (Pencina et al., 2023).
  • Route: Sublingual dosing did not raise blood NMN or NAD+ more than oral dosing, but raised 2PY and 4PY faster (Wakabayashi et al., 2026; Meiji-run).
  • Genetic polymorphisms: No pharmacogenetic dosing guidance exists; rs10496731, which raises 2PY and 4PY, is the only variant linked to NMN-pathway metabolites (Ferrell et al., 2024).
  • Sex differences: No sex-specific dosing exists; metabolic benefit was shown in women (Yoshino et al., 2021) and muscle trials mostly in men (Igarashi et al., 2022), so trial evidence for each sex differs by outcome.
  • Age considerations: Older adults showed the blood-pressure signal (Zhang et al., 2026) but no muscle benefit (Prokopidis et al., 2025); aged-mouse kidney data favor the lower end of the dose range at advanced ages.
  • Baseline biomarkers: Because NAD+ response varies widely (Kuerec et al., 2024), measuring blood NAD+ before and after 4–8 weeks allows dose adjustment to a measured response.
  • Pre-existing conditions: Overweight and prediabetic adults showed the clearest metabolic responses; people with cancer or kidney disease face the speculative risks and typically involve their physician.

Discontinuation & Cycling

  • Lifelong or short-term: Trials lasted 2–24 weeks; longevity users usually take NMN open-ended, but no human data cover multi-year use.
  • Withdrawal effects: None have been reported; blood NAD+ is expected to drift back toward baseline after stopping, though this has not been formally studied.
  • Tapering: Not needed; no rebound or dependence has been described, so NMN can be stopped at once.
  • Cycling: No evidence shows that cycling maintains efficacy; some users take periodic breaks to limit theoretical long-term risks, a practice that is untested.

Sourcing and Quality

  • Purity and identity: Testing by ChromaDex, an NR seller, reported that 14 of 22 NMN products sold on Amazon held less than 1% of the labeled NMN, three with none detected (NutraIngredients).
  • Third-party testing: Lot-specific certificates of analysis from an independent, accredited laboratory, or a ConsumerLab, USP (United States Pharmacopeia) or NSF International listing, verify NMN content and screen for contaminants.
  • Form: β-NMN is the active form; EFSA assessed chemically synthesized β-NMN (EFSA, 2026). Reduced NMN and MIB-626’s distinct crystalline form are different materials with less human data.
  • Ingredient suppliers: Suppliers with regulatory dossiers include Effepharm (Uthever; FDA notification list, EFSA, 2026) and Kingdomway and SyncoZymes, which received 2025 FDA letters, as reported by NutraIngredients (FDA’s letters not retrievable); Mitsubishi Corporation Life Sciences supplied several Japanese trials.
  • Storage and stability: NMN degrades with heat and humidity; cool, dry storage in sealed containers is standard practice (FoundMyFitness clip).

Practical Considerations

  • Time to effect: Blood NAD+ rises within 30 days (Yi et al., 2023); trial effects on endurance, walking or sleep were measured after 6–12 weeks, so earlier judgments of benefit are premature.
  • Common pitfalls: Buying untested products, treating a higher NAD+ reading as proof of health benefit, exceeding tested doses, and using NMN in place of exercise, sleep and diet.
  • Regulatory status (United States): FDA excluded NMN from supplements in 2022, then concluded in September 2025 it is not excluded, as reported by NutraIngredients (FDA’s response letter FDA-2023-P-0872-2754 not retrievable); FDA lists an NMN ingredient notification answered January 2026 (FDA new dietary ingredient list).
  • Regulatory sources and advocacy: FDA’s petition response (FDA-2023-P-0872-2754; regulations.gov blocked retrieval for this review) answered a petition from the Natural Products Association and Alliance for Natural Health USA, as reported by NutraIngredients; the association’s member companies earn revenue from supplement sales.
  • Regulatory status (European Union): NMN is a novel food; EFSA’s 2026 opinion found β-NMN safe at 300 mg/day for adults, with final authorization resting with the European Commission (EFSA, 2026).
  • Cost and payers: NMN is moderately priced and paid out of pocket; with no insurer or health system covering it or its competitors, payer-driven bias is not a factor, while manufacturer interests are.

Interaction with Foundational Habits

  • Sleep: Direction: possibly potentiating. One older-adult trial reported better sleep-questionnaire scores (Morifuji et al., 2024); afternoon drowsiness fell with NMN and placebo alike (Kim et al., 2022), and pooled data show no sleep benefit (Gao et al., 2026); no insomnia signal has been reported, so morning or afternoon dosing both fit sleep routines.
  • Nutrition: Direction: indirect. Food supplies under 2 mg/day of NMN (Yoshino et al., 2021); dietary niacin and tryptophan also feed NAD+. Folate, B12 and choline intake support clearance of surplus nicotinamide.
  • Exercise: Direction: potentiating and blunting. NMN plus training improved runners’ ventilatory thresholds (Liao et al., 2021), yet high doses blunted mitochondrial adaptation after one session (Yang et al., 2026); exercise itself raises NAMPT, a natural NAD+ booster.
  • Stress management: Direction: none established. One trial collected stress data without a reported benefit (Morifuji et al., 2024); no effect on cortisol or stress response has been shown, so stress practices remain independent of NMN use.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes reference points: kidney function (creatinine with eGFR), liver enzymes (ALT), homocysteine, seated blood pressure, and, where available, a whole-blood NAD+ measurement. These values make it possible to detect safety changes and to judge response against the individual’s own starting point.

Ongoing monitoring follows a simple cadence: home blood pressure (and glucose for anyone on diabetes medication) weekly for the first 4 weeks; blood NAD+ at 4–8 weeks to confirm absorption; then kidney, liver and homocysteine markers at 3 months and every 6–12 months thereafter. Success is defined as a measurable NAD+ rise, stable safety markers, and improvement in at least one targeted outcome, such as blood pressure or endurance.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 7–55 U/L (standard reference range) Safety check; a rise changes use Pooled trials showed no ALT rise (Yang et al., 2026); pair with AST (aspartate aminotransferase); no fasting needed
Creatinine with eGFR Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL (standard reference range) Safety check for the aged-mouse kidney signal Avoid heavy exercise and large protein meals 24 h before; same lab each time
Blood pressure Below 120/80 mmHg, the normal category of the ACC/AHA 2017 guideline Expected to change; small diastolic drop Source: Whelton et al., 2018 (ACC/AHA = American College of Cardiology/American Heart Association; their clinician members earn revenue from treating the high blood pressure these categories define, though not from NMN); conventional reference range is the same below-120/80 normal category; seated morning home readings
Whole-blood NAD+ No established target; track rise from own baseline Expected to change; confirms absorption and dose response Specialty test; response varies widely (Kuerec et al., 2024); same lab and time of day
Homocysteine 5–15 µmol/L (standard reference range) Safety check for methyl-group drain Fasting sample; pair with vitamin B12 and folate

Qualitative markers worth tracking:

  • Energy and daytime drowsiness
  • Exercise tolerance and recovery
  • Sleep quality
  • Mental clarity
  • Digestive comfort or flushing

Emerging Research

  • One-year biological-age trial: 240 middle-aged and older adults take 350 mg/day or placebo for 12 months; primary endpoint is a composite aging-clock score; completion December 2026 (NCT06592859). A positive result would strengthen the biomarker case; a null would weaken it.
  • Diabetic kidney disease: Phase 2, 156 older adults, MIB-626 versus placebo for 6 months; primary endpoint urine albumin-to-creatinine ratio (protein leakage) (NCT05759468). A positive result would ease kidney-safety concerns; a null would leave them open.
  • Immune aging: 126 adults with metabolic disorders take 1,000 mg/day sustained-release NMN or placebo for 26 weeks; primary endpoint is the share of senescent CD8+ T cells (aged killer immune cells) (NCT06907329). A positive result would add an immune benefit; a null would not.
  • Exercise tolerance in older adults: 40 healthy older adults compare NMN, NMN with trimethylglycine, and control; primary endpoint is time to fatigue on a cycle ergometer (NCT07144527). A positive result would extend the endurance item to older adults; a null would confine it to younger ones.
  • Heart tissue delivery: Phase 2, 90 cardiac-surgery patients; primary endpoint is heart-muscle NAD+ (NCT07013591). A positive result would show oral NMN reaches the human heart; a null would question tissue delivery.
  • Cardiovascular safety of 4PY: The 4PY link to cardiovascular events (Ferrell et al., 2024) has not been tested under NMN; trials measuring 4PY with vascular inflammation markers could strengthen or weaken the safety case.
  • Mouse lifespan replication: The female-only lifespan gain (Kane et al., 2024) awaits peer review and independent replication, which could confirm or refute the main animal rationale.
  • Precursor comparisons: Comparable blood NAD+ rises from NMN and NR, possibly via gut-bacterial conversion (Christen et al., 2026), raise the question of whether NMN offers anything unique; head-to-head outcome trials could resolve it.

Conclusion

NMN is a vitamin B3–derived supplement that reliably raises a helper molecule that cells use for energy and repair and that declines with age. Whether raising it makes people healthier remains largely unsettled. The most consistent human signals are a small drop in the lower blood-pressure number, with the upper number also falling in people over sixty, and modest gains in endurance and self-rated health. Effects on blood sugar, cholesterol, muscle strength and sleep have been inconsistent, and the longer lifespan seen in female mice has never been tested in people.

Short-term safety looks favorable: in studies lasting up to six months, side effects occurred about as often as with placebo. Longer-term questions remain open, based on population, animal, cell and short tissue-level human studies: a breakdown product linked to heart disease, kidney inflammation in old mice, possible support of tumor-promoting inflammation, and dulling of the muscle’s response to exercise.

The evidence base is thin. Most studies were small and brief, and most were run or paid for by companies that make or sell NMN. Prominent voices on both sides have commercial ties to NMN or to competing products, industry trade groups shaped its legal status, and the blood-pressure target used for tracking comes from heart-medicine societies whose members are paid to treat high blood pressure. Product quality varies widely. For health-focused adults, NMN is a plausible but unproven add-on whose benefits, if real, appear modest and whose long-term risks are not yet known.

Top - Benefits - Risks - Protocol